FLT3 Inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer
作者： P Brown , D Small
DOI: 10.1016/J.EJCA.2003.08.030
关键词:
摘要: The area of molecularly-targeted cancer therapeutics is generating tremendous interest and excitement. While clinical investigation these agents has been largely limited to adults, trials for paediatric patients with many are now underway. This paper reviews the current status therapies malignancies, special attention given one class agents, inhibitors FLT3 receptor tyrosine kinase. expressed activated in human leukemias, including a significant percentage pediatric AML infant childhood ALL, especially setting MLL gene rearrangement. Activating mutations portend poor prognosis AML. Activated can be effectively selectively targeted by small molecule inhibitors, have shown promise early phase adults Limited preclinical data MLL-rearranged ALL also reported. Challenges future directions use other discussed.
elsevier.com
sci-hub.se 参考文章(127)
Hilary J. McKenna, Kim L. Stocking, Robert E. Miller, Kenneth Brasel, Thibaut De Smedt, Eugene Maraskovsky, Charles R. Maliszewski, David H. Lynch, Jeffrey Smith, Bali Pulendran, Eileen R. Roux, Mark Teepe, Stewart D. Lyman, Jacques J. Peschon, Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. ,vol. 95, pp. 3489- 3497 ,(2000) , 10.1182/BLOOD.V95.11.3489
O Rosnet, C Schiff, MJ Pebusque, S Marchetto, C Tonnelle, Y Toiron, F Birg, D Birnbaum, Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. ,vol. 82, pp. 1110- 1119 ,(1993) , 10.1182/BLOOD.V82.4.1110.1110
D. Acton, J. Domen, H. Jacobs, M. Vlaar, S. Korsmeyer, A. Berns, Collaboration of PIM-1 and BCL-2 in Lymphomagenesis Current Topics in Microbiology and Immunology. ,vol. 182, pp. 293- 298 ,(1992) , 10.1007/978-3-642-77633-5_36
Quentmeier H, Meierhoff G, Drexler Hg, Dehmel U, Birnbaum D, Rosnet O, Dirks W, Gruss Hj, Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. ,vol. 9, pp. 1368- 1372 ,(1995)
Lyman, Biology of flt3 ligand and receptor. International Journal of Hematology. ,vol. 62, pp. 63- 73 ,(1995) , 10.1016/0925-5710(95)00389-A
SD Lyman, L James, L Johnson, K Brasel, P de Vries, SS Escobar, H Downey, RR Splett, MP Beckmann, HJ McKenna, Cloning of the human homologue of the murine flt3 ligand : a growth factor for early hematopoietic progenitor cells Blood. ,vol. 83, pp. 2795- 2801 ,(1994) , 10.1182/BLOOD.V83.10.2795.2795
Yukimasa Shiotsu, Leonard M. Neckers, Ivo Wortman, Won G. An, Theodor W. Schulte, Shiro Soga, Chikara Murakata, Tatsuya Tamaoki, Shiro Akinaga, Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex Blood. ,vol. 96, pp. 2284- 2291 ,(2000) , 10.1182/BLOOD.V96.6.2284
Y Minami, H Kiyoi, Y Yamamoto, K Yamamoto, R Ueda, H Saito, T Naoe, Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. ,vol. 16, pp. 1535- 1540 ,(2002) , 10.1038/SJ.LEU.2402558
F Birg, M Courcoul, O Rosnet, F Bardin, MJ Pebusque, S Marchetto, A Tabilio, P Mannoni, D Birnbaum, Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages Blood. ,vol. 80, pp. 2584- 2593 ,(1992) , 10.1182/BLOOD.V80.10.2584.2584
Thelma Angeles, John Lamb, John T. Isaacs, Craig A. Dionne, Daniel J. George, Jitesh Jani, Chikara Murakata, Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Research. ,vol. 59, pp. 2395- 2401 ,(1999)